65,437 trials
MULTIPLE MYELOMA
Primary: Antithrombotic Effect of VELCADE in a Malignancy Associated With a Hypercoagulable State in Patients With Relapsed/Refractory Multiple Myeloma.
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Breast Cancer · Osteoporosis
Primary: Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD) — 2.66 Percentage of the baseline value — p=0.01
Presbyopia
Primary: Overall Vision — 8.5; 8.3 units on a scale
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.13; -0.63; -0.71 percentage of Glycosylated Hemoglobin — p=<0.001
Amblyopia
Primary: Visual Acuity Mean Score in the Amblyopic Eye — 0.23; 0.22; 0.54; 0.50 logMAR units — p=0.21
Influenza
Primary: Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Axillary Temperature ≥ 101°F (38.3°C). — 4; 1 participants
Chronic Kidney Disease
Primary: Comparison of Urea Removal Under Conditions of Routine Hemodialysis. — 1.64; 1.61; 1.42; 1.40 ratio
Ocular Discomfort
Primary: Comfort-related Symptoms/Complaints — 89.0; 88.3; 81.7; 81.9 Units on a scale
High Blood Pressure · Metabolic Syndrome · Insulin Resistance
Primary: Mean Change in Endothelial Function as Measured by Myocardial Blood Flow (MBF) From Baseline and After 12 Weeks of Treatment — 0.06; 0.12 mL/g/min
B-Cell Chronic Lymphocytic Leukemia
Primary: Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment — 23.65; 16.48 months — p=<0.001
Postmenopausal Osteoporosis
Primary: Bone Mineral Density BMD (Percentage) Change in Lumber Spine After 12 Months — 1.22; 2.17 percentage of BMD — p=0.26
Migraine
Primary: The Primary Outcome is Defined as Average Change in Frequency of Migraine Attacks Over Each 4-week Interval of the Treatment Period as Compared to the 4-week Baseline…
Influenza
Primary: Categorical Summary of Pain or Other Discomfort Immediately After Vaccination and on Days 3 and 7 Post-vaccination — 85; 75; 4; 2 Participants